(Q38201749)

30 August 2017

0 references

Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review (English)

1 reference

30 August 2017

1 reference

3

Joseph Peuskens

1 reference

30 August 2017

Marc De Hert

1

1 reference

30 August 2017

Johan Detraux

series ordinal

2

1 reference

30 August 2017

language of work or name

English

0 references

publication date

3 April 2014

1 reference

Expert Opinion on Drug Safety

30 August 2017

published in

1 reference

30 August 2017

volume

13

1 reference

30 August 2017

issue

5

1 reference

30 August 2017

page(s)

605-624

1 reference

Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

A Survey of Sexual Side Effects Among Severely Mentally Ill Patients Taking Psychotropic Medications: Impact on Compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Sexual side effects of pharmacological treatment of psychiatric diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Sexual dysfunction in schizophrenia: focus on recent evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Change in sexual dysfunction with aripiprazole: a switching or add-on study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Antipsychotic-induced sexual dysfunction and its management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Tolerability of paliperidone: a meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

A 6-month prospective observational study on the effects of quetiapine on sexual functioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Changes in sexual function for outpatients with schizophrenia or other psychotic disorders treated with ziprasidone in clinical practice settings: a 3-month prospective, observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Sexual function of patients with schizophrenia receiving first-generation (FGA) or second-generation antipsychotic (SGA) treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Iloperidone for the treatment of schizophrenia: an updated clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Asenapine: a synthesis of efficacy data in bipolar mania and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Review of the safety, efficacy, and side effect profile of asenapine in the treatment of bipolar 1 disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Iloperidone: a clinical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Iloperidone: A new drug for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Prolactin, subjective well-being and sexual dysfunction: an open label observational study comparing quetiapine with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Prolactin levels and sexual adverse effects in patients with schizophrenia during antipsychotic treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

No association between hormonal abnormality and sexual dysfunction in Japanese schizophrenia patients treated with antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Prolactin levels and adverse events in patients treated with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Sexual dysfunction and hyperprolactinemia in Japanese schizophrenic patients taking antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

A new atypical antipsychotic: quetiapine-induced sexual dysfunctions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

The impact of hyperprolactinaemia on sexual function in patients with psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Antipsychotics and hyperprolactinaemia: clinical recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Current guidelines and their recommendations for prolactin monitoring in psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Non-neurological and metabolic side effects in the Cost Utility of the Latest Antipsychotics in Schizophrenia Randomised Controlled Trial (CUtLASS-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Update on the development of lurasidone as a treatment for patients with acute schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Sexual dysfunction in people with prodromal or first-episode psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

The impact of mental illness on sexual dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Sexual dysfunction in male schizophrenia: influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Serum prolactin and macroprolactin levels among outpatients with major depressive disorder following the administration of selective serotonin-reuptake inhibitors: a cross-sectional pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Physical health monitoring of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Medication-induced hyperprolactinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Prolactin awareness: an essential consideration for physical health in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Clinical questions and uncertainty--prolactin measurement in patients with schizophrenia and bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

A review of hyperprolactinaemia and severe mental illness: are there implications for clinical biochemistry?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Psychotropic-induced hyperprolactinemia: a clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

A systematic review on clinical management of antipsychotic-induced sexual dysfunction in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Hyperprolactinaemia caused by antipsychotic drugs. Endocrine antipsychotic side effects must be systemically assessed

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Drug Insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Sexual dysfunction related to psychotropic drugs: a critical review part II: antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Cabergoline-induced psychotic exacerbation in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Not only dopamine D2 receptors involved in Peony-Glycyrrhiza Decoction, an herbal preparation against antipsychotic-associated hyperprolactinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Psychometric properties of the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX) in patients with schizophrenia and other psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

The Antipsychotics and Sexual Functioning Questionnaire (ASFQ): preliminary evidence for reliability and validity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Reliability and validity of a new sexual function questionnaire (Nagoya Sexual Function Questionnaire) for schizophrenic patients taking antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Sexual dysfunction in Japanese patients with schizophrenia treated with antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

A comparative study of sexual dysfunction involving risperidone, quetiapine, and olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Study of Sexuality-Related Characteristics in Young Adults With Schizophrenia Treated With Novel Neuroleptics and in a Comparison Group of Young Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Sexual side effects of novel antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

Sexual Dysfunction in First-Episode Schizophrenia Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.906579

10.1517/14740338.2014.906579

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference